Abstract 4282: Long-term Clinical Results of Tricuspid Valve Replacement
We estimated our surgical result of tricuspid valve replacement(TVR) for adult population(≥18years old) with an emphasis on operative mortality and re-TVR according to the type of prosthetic valve. Between 1978 and 2005, we performed 157 TVR (62 male and 95 female, the mean age 54±14 years old, range18–78). Among those, re-TVR was done in 29 and other 128 underwent initial replacement. The prosthesis used was mechanical in 35 and biological in 122. The disease that required TVR were combined valvular disease in 75, congenital anomaly in 39 (Ebstein’s anomaly 14), prosthetic valve dysfunction in 24, infective endocarditis in 6 and isolated tricuspid lesion and others in 13. The mean follow-up was 8.6±6.8 years and cumulative follow-up was 1344 patient-years. There were 22 in-hospital deaths (14%) and 36 late deaths. Actual survival rate at 3, 5, 10 years was 82%, 79% and 67% for mechanical valves, and 79%, 73% and 65% for bioprosthetic valves respectively (p=0.854). Freedom from re-TVR rate at 5, 10 years was 88% and 74% for mechanical valves, and 97% and 86% for bioprosthetic valves (p=0.263). Gender (male>female, p=0.0125) and acquired valvular disease (p=0.0069) were the significant predictors of hospital mortality, and age at operation was the only predictor of re-TVR requirement.
Conclusions: Although hospital mortality of TVR was relatively high because of the severity and complexity of the illness of the candidates, long-term results were satisfactory. Our results indicated no significant priority in long-term survival and freedom from re-TVR between mechanical and bioprosthetic valve.